Latest HPV OncoTect Stories
BEDFORD, Mass., July 18, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the NVVP (Netherlands Society for Pathology) has approved the use of the Hologic Cervista HPV HR test for detecting human papillomavirus in the Dutch national cervical screening programme.[i]...
Singapore, June 12, 2012 - (ACN Newswire) - A team of scientists from A*STAR's Institute of Medical Biology (IMB) and Genome Institute of Singapore (GIS) together with clinicians from Boston's Brigham and Women's Hospital (BWH) have identified a unique set of cells in the cervix that are the cause of human papillomaviruses (HPV) related cervical cancers. Significantly, the team also showed that these cells do not regenerate when excised. These findings have immense clinical implications in...
SAN DIEGO, May 2, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. patent application pending) might, once available, be particularly useful for the determination of carrier status in males. The Company's HPV detection assay is a unique, proprietary(1) method that...
Women ages 21 to 65 should have a Pap smear every three years, according to new guidelines from the United States Preventive Services Task Force (USPSTF). Based on the evidence, women between the ages of 30 and 65 can safely extend the screening interval to once every five years if they undergo the humanpapillomavirus (HPV) test at the same time as the Pap. The guideline is being published early online in Annals of Internal Medicine. The USPSTF recommends against screening for cervical...
GERMANTOWN, Maryland and HILDEN, Germany, March 15, 2012 /PRNewswire/ -- - U.S. Preventive Services Task Force (USPSTF) changes its recommendation to support HPV screening in conjunction with cytology (Pap test) for cervical cancer protection - Other U.S. organizations, including American Cancer Society and leading professional groups, reaffirm guidelines supporting benefits of co-testing with HPV and Pap tests...
PLEASANTON, Calif., March 15, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today welcomed new guidelines for the prevention and early detection of cervical cancer issued jointly by the American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP). For the first time, these professional organizations together issued guidelines that using human papillomavirus (HPV) testing in...
Human papillomavirus (HPV) testing of self-collected specimens may be a more effective way to screen for cervical cancer in low-resource settings compared to visual inspection with acetic acid (VIA) and liquid-based cytology (LBC), according to a study published January 23 in the Journal of the National Cancer Institute. Cervical cancer is the third most common cancer found in women with approximately 530,000 new cases each year resulting in an estimated 275,000 deaths. In developed...
LONDON, January 23, 2012 /PRNewswire/ -- Roche sets up co -marketing agreement with private laboratory to support greater access to HPV testing In an innovative commercial agreement, leading healthcare company Roche and foremost private cellular pathology laboratory Unilabs-IHS, are collaborating to help make state-of-the art testing for signs of cervical cancer more accessible to thousands of women in London and throughout the UK. Roche's leading-edge and fully...
The results of a 5-year study by Dutch scientists indicate that a DNA test able to detect the virus usually responsible for cervical cancer should be combined with existing smear tests for more thorough preventative care. Researchers at the VU University Medical Centre in Amsterdam reported the results of their study of 45,000 women in The Lancet Oncology this week. They say their data provide the most compelling evidence to-date supporting human papillomavirus (HPV) testing in women over...
BEDFORD, Mass., Dec. 15, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus...
